Drugs targeting intracellular molecule

JAK inhibitor and syk inhibitor

Kunihiro Yamaoka, Kazuyoshi Saito, Yoshiya Tanaka

Research output: Contribution to journalArticle

Abstract

Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.

Original languageEnglish
Pages (from-to)23-27
Number of pages5
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume44
Issue number1
DOIs
Publication statusPublished - 2013 Jan
Externally publishedYes

Fingerprint

Janus Kinases
Drug Delivery Systems
Rheumatoid Arthritis
Clinical Trials
Therapeutics
Arthritis
Interleukin-6
Cytoplasm
Pathology
Cytokines

Keywords

  • JAK
  • Rheumatoid arthritis
  • Syk

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Drugs targeting intracellular molecule : JAK inhibitor and syk inhibitor. / Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 44, No. 1, 01.2013, p. 23-27.

Research output: Contribution to journalArticle

Yamaoka, Kunihiro ; Saito, Kazuyoshi ; Tanaka, Yoshiya. / Drugs targeting intracellular molecule : JAK inhibitor and syk inhibitor. In: Japanese Journal of Clinical Pharmacology and Therapeutics. 2013 ; Vol. 44, No. 1. pp. 23-27.
@article{3d240bf8eaf146da92c48dde5e10afa6,
title = "Drugs targeting intracellular molecule: JAK inhibitor and syk inhibitor",
abstract = "Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.",
keywords = "JAK, Rheumatoid arthritis, Syk",
author = "Kunihiro Yamaoka and Kazuyoshi Saito and Yoshiya Tanaka",
year = "2013",
month = "1",
doi = "10.3999/jscpt.44.23",
language = "English",
volume = "44",
pages = "23--27",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "1",

}

TY - JOUR

T1 - Drugs targeting intracellular molecule

T2 - JAK inhibitor and syk inhibitor

AU - Yamaoka, Kunihiro

AU - Saito, Kazuyoshi

AU - Tanaka, Yoshiya

PY - 2013/1

Y1 - 2013/1

N2 - Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.

AB - Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.

KW - JAK

KW - Rheumatoid arthritis

KW - Syk

UR - http://www.scopus.com/inward/record.url?scp=84874254927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874254927&partnerID=8YFLogxK

U2 - 10.3999/jscpt.44.23

DO - 10.3999/jscpt.44.23

M3 - Article

VL - 44

SP - 23

EP - 27

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 1

ER -